TauC3 Biologics, a biotechnology company focused on developing therapies for neurodegenerative diseases, has secured approximately $2.5 million in new investor commitments, extending its operational runway to Q2 2027 and accelerating the development of its lead antibody program, TBL-100. The company is preparing for a planned £25 million Series A financing round aimed at initiating first-in-human studies.

TBL-100 is designed to selectively target tauC3, a truncated and highly toxic form of the tau protein that has been implicated in the early stages of several devastating neurodegenerative disorders, including frontotemporal dementia, progressive supranuclear palsy, and Alzheimer’s disease.

Tau proteins play a critical role in maintaining healthy neuronal structure and function. When tau becomes abnormally modified, it can misfold and aggregate, disrupting cellular processes. TauC3 is particularly harmful due to its increased propensity for aggregation and ability to propagate pathology between cells. By selectively targeting tauC3, TBL-100 aims to remove these toxic protein complexes both inside and outside brain cells, supporting neuronal health, reducing inflammation, and slowing the progression of tau-driven disease.

“The challenge with previous tau-targeting therapies has often been a lack of specificity,” said Daniel Chain, CEO of TauC3 Biologics. “By focusing on tauC3, the toxic species that drives disease progression, we believe we can overcome a fundamental limitation of earlier approaches and deliver meaningful clinical benefit.”

The planned Series A round will support the company’s transition from preclinical research to clinical-stage development, a key milestone in its mission to develop transformative treatments for fatal neurodegenerative diseases.

“With this new investment, we are well positioned to advance TBL-100 toward clinical studies, translating our scientific insights into therapies that could significantly impact the lives of patients and families affected by these disorders,” added Chain.